Testing of PD-L1 expression (available in the registry from 1-January-2018, thus not registered for all patients with treatment/survival data in the cohort) in the tumor cells was recorded for >90% of the patients receiving combination immunotherapy and for approximately 80% of the patients treated with monotherapy (Tables 1 and 2). Here, CD274 is linked to neoplasm.